Rheumatology

Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals

Stephen Padilla, 19 hours ago

A collaborative clinic led by a pharmacist helps patients with gout to attain better clinical outcomes in the management of their condition, even in the presence of renal impairment, reports a Singapore study. The clinic provides safe, stepwise increments of urate-lowering therapy (ULT) in addition to serum uric acid (SUA) monitoring and adherence reinforcement through frequent initial visits.

Tigulixostat for lowering uric acid scores high in phase II trial

5 days ago

Treatment with the nonpurine xanthine oxidase inhibitor tigulixostat leads to a significant reduction in serum uric acid (sUA) levels while having an acceptable safety profile, as shown in data from the multicentre, double-blind, parallel-group, dose-finding phase II CLUE trial.

Drinking tied to RA disease activity

Jairia Dela Cruz, 5 days ago

Alcohol consumption appears to influence outcomes in patients with rheumatoid arthritis (RA), with a recent study showing that low to moderate drinkers have a lower disease activity and higher health-related quality of life than abstainers.

Can RA patients taper MTX from targeted therapy?

18 Jan 2023

A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.

Deucravacitinib bestows benefits in Asian patients with plaque psoriasis

Roshini Claire Anthony, 04 Oct 2022

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Baricitinib delays, lowers frequency of flares in JIA

Roshini Claire Anthony, 23 Jun 2022

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients

Roshini Claire Anthony, 20 Jun 2022

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Bimekizumab shows promise across the spectrum of axial spondyloarthritis

Elaine Soliven, 18 Jun 2022

Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.

JAK inhibition with upadacitinib works well in nr-axSpA

Elvira Manzano, 16 Jun 2022

Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.

Sarilumab shows potential for relapsing polymyalgia rheumatica

Audrey Abella, 15 Jun 2022

The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.